文章
醫療新知 > 胰臟癌治療新發現 學者:重大勝利

胰臟癌治療新發現 學者:重大勝利

04-06-2016

 

(法新社芝加哥4日綜合外電報導)根據今天在美國臨床腫瘤學會芝加哥年會發表的歐洲研究報告,結合兩種化療藥,在治療胰臟癌上出現令人鼓舞的結果,大舉改善5年存活率。學者稱這項發現為重大勝利。 根據取自732名患者的數據,患者在開刀切除胰臟癌後,以口服化療藥物capecitabine搭配胰臟癌第一線標準治療藥物gemcitabine,長期存活率可從16%升至29%。 美國凱斯西儲大學(Case Western Reserve University)的克里希納瑪迪(Smitha Krishnamurthi)說:「胰臟癌仍屬治療難度最高的癌症之一。增加1項一般化療不僅改善患者存活率,還不大影響患者生活品質,這項發現實屬重大勝利。」 克里希納瑪迪並沒有參與研究。 研究主筆、英國利物浦大學(University of Liverpool)的尼奧塔勒莫斯(John Neoptolemos)說,儘管診斷出胰臟癌的患者大多並非手術人選,這份研究報告顯示,可以接受手術的患者「有很好的機會可以透過2種常見化療藥來打擊癌症」。

 

延申閱讀 :

Two-drug regimen shows promise against pancreatic cancer

 
Pancreatic cancer
Axial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domain

A combination of two chemotherapy drugs has shown promising results in fighting pancreatic cancer, significantly improving five-year survival rates, according to a European study presented Friday.

The trial showed that patients who take the oral drug capecitabine in addition to treatment with the commonly-used intravenous drug gemcitabine after surgical removal of survived longer without significant increase in negative side effects.

It was one of the largest trials ever conducted in pancreatic cancer, involving 732 patients.

The study was presented at the American Society of Clinical Oncology's annual meeting, the world's largest conference on cancer, currently being held in Chicago.

"Pancreatic cancer remains one of the most hard-to-treat cancers. It is a major win to find that adding a generic chemotherapy not only improves survival for these patients, but does so with little effect on patients' quality of life," said Smitha Krishnamurthi of Case Western Reserve University, who was not a part of the study.

Although most people diagnosed with pancreatic cancer are not candidates for surgery, the findings show that those who can have surgery "have a fighting chance of surviving this cancer with the combination of two commonly used chemotherapies," said John Neoptolemos, the study's lead author of the University of Liverpool in Britain.

The study showed a five-year survival rate of 28.8 percent among the group treated with both capecitabine and gemcitabine for six months, compared with 16.3 percent for the group that received gemcitabine alone during that time.

The median overall survival rate was 28 months with the combination of drugs, compared to 25.5 months with gemcitabine alone.

"The difference in median survival may seem modest, but the improvement in long-term survival is substantial for this cancer," Neoptolemos said in a statement.

The study's determination that the gemcitabine-capecitabine treatment is safe allows researchers to consider what other treatments could be added effectively.

According to the World Health Organization, 338,000 people in the world were diagnosed with pancreatic cancer in 2012, with the highest number of cases in North America and Europe.

Pancreatic cancer is the fourth-leading cause of cancer death in the United States, with 41,780 deaths expected in 2016.

medicalxpress.com/news/2016-06-two-drug-regimen-pancreatic-cancer.html

 

疑難排解

會員註冊


或許你會想看
2023年醫院管理局研討大會 創建疫後新世代醫療:持續發展.科技創新.人才匯聚
2023年醫院管理局研討大會 醫院管理局行政總裁高拔陞醫生 主題演講 2023 年 5 月 16 日 創建疫後 […]
SANTRO-CAHON-CSTRO 「新冠流行期間癌症患者的治療考慮」互動研討會完美落幕
周伯儒, 香港大學李嘉誠醫學院四年級醫學生 Chi Lin, 內布拉斯加大學醫學中心 Feng-Ming (S […]
「人類乳頭瘤病毒 (HPV) DNA檢測與子宮頸細胞檢驗 (液基薄層柏氏抹片)的合併檢測」(合併檢測) 服務
家計會推出包括HPV DNA檢測的合併檢測 能於較早期發現子宮頸癌前病變並減癌症風險 香港家庭計劃指導會 (家 […]
中大研究發現乙肝康復者的嚴重肝病併發症風險會隨時間下降 唯仍須注意患肝癌風險 建議接受長期肝癌監測
本港約54萬人患有乙型肝炎,部分人可經藥物或自身痊癒,達至「乙肝病毒表面抗原清除」,成為「乙肝康復者」。香港中 […]
中大研究發現乙肝康復者的嚴重肝病併發症風險會隨時間下降 唯仍須注意患肝癌風險 建議接受長期肝癌監測
本港約54萬人患有乙型肝炎,部分人可經藥物或自身痊癒,達至「乙肝病毒表面抗原清除」,成為「乙肝康復者」。香港中 […]
《香港百歲老人研究》調查研究結果發布
《香港百歲老人研究》 身心健康、認知及自理能力下降 研究團隊籲加強支援服務 【新聞稿2023年3月13日】 香 […]
港大生物學家揭示防止DNA受損機制 加深對癌症形成的理解
不當的細胞分裂有可能導致癌症的發生,因此科學家一直在尋找維持細胞分裂穩定的機制。最近,香港大學(港大)生物科學 […]
城大發現促使癌細胞擴散的蛋白質 望為癌症治療提供新治療靶點
香港城市大學(城大)研究團隊發現,一種名為「賴氨酸羥化酶1」(LH1)的蛋白質,是促使肝細胞癌和胰臟導管腺癌的 […]
中大完成全球首例機械人輔助支氣管鏡微波消融術治療肺轉移
身體不同部位的惡性腫瘤出現癌細胞轉移時,常會轉移至肺部。以傳統手術方式切除肺轉移腫瘤,很大機會造成手術創傷,而 […]
癌症病人選用新一代口服化療藥,在家治療可降低感染風險
癌症病人選用新一代口服化療藥, 在家治療可降低感染風險 疫情期間,不少病人進出醫療場所接受化療都少不免擔心受到 […]
中大發現間皮瘤的女性發病率上升 高收入國家的發病率較高
間皮瘤(Mesothelioma)由於治癒率較其他癌症低,患者的五年存活率平均僅有8%,醫學界一直努力尋求間皮 […]
港大化學生物學家拆解一類「組蛋白修飾」 為開發相關抗癌新藥帶來曙光
由香港大學(港大)化學系李祥教授率領的研究團隊,與港大生物科學學院翟元樑博士及港大生物醫學學院黃永瀚博士和鮑秀 […]